600521.SHG Zhejiang Huahai Pharmaceutical Co Ltd
- Market cap
- CNY 26.8B
- P/E
- 28.4x
- P/B
- 2.46x
- ROE
- 14.0%
- Dividend yield
- 2.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600521.SHG undervalued?
Graham number600521.SHG trades 76.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Huahai Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Huahai Pharmaceutical Co Ltd yet.
Zhejiang Huahai Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In …
Full company profileZhejiang Huahai Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Huahai Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.09B | 5.00B | 5.09B | 5.39B | 6.49B | 6.64B | 8.27B | 8.31B | 9.55B | 8.59B | 9.90B |
| Gross Profit | 2.04B | 2.80B | 2.95B | 3.19B | 4.10B | 3.97B | 5.09B | 4.93B | 5.81B | 5.17B | 5.91B |
| Operating Income | 508M | 791M | 475M | 824M | 1.29B | 868M | 1.55B | 1.12B | 1.47B | 834M | 1.82B |
| EBITDA | 750M | 1.14B | 701M | 1.24B | 1.85B | 1.05B | 2.23B | 2.14B | 2.51B | 1.69B | 1.96B |
| Net Income | 501M | 639M | 108M | 570M | 930M | 488M | 1.17B | 830M | 1.12B | 266M | 1.41B |
| EPS | 0.37 | 0.46 | 0.08 | 0.39 | 0.64 | 0.34 | 0.80 | 0.57 | 0.77 | 0.18 | 0.94 |
| Balance Sheet | |||||||||||
| Total Assets | 6.73B | 8.27B | 10.4B | 10.7B | 13.0B | 15.5B | 18.2B | 18.6B | 20.3B | 21.5B | 22.5B |
| Total Liabilities | 2.15B | 3.21B | 6.16B | 4.95B | 6.27B | 8.69B | 10.4B | 10.3B | 11.2B | 12.0B | 12.1B |
| Shareholders' Equity | 4.38B | 4.88B | 4.07B | 5.61B | 6.51B | 6.56B | 7.55B | 8.08B | 8.90B | 9.44B | 10.1B |
| Cash & Short-term Investments | 792M | 691M | 911M | 1.50B | 2.21B | 1.88B | 1.51B | 1.44B | 1.60B | 1.50B | 2.18B |
| Total Debt | 1.02B | 1.81B | 3.55B | 3.31B | 4.05B | 5.63B | 6.86B | 5.65B | 6.52B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 433M | 546M | 67.9M | 1.75B | 1.56B | 938M | 1.24B | 2.22B | 2.17B | 1.23B | - |
| Capital Expenditure | 733M | 795M | 1.12B | 794M | 1.28B | 2.43B | 2.32B | 1.59B | 1.85B | 1.97B | 1.44B |
| Free Cash Flow | -300M | -248M | -1.06B | 960M | 279M | -1.50B | -1.07B | 625M | 319M | -736M | 601M |
| Ratios | |||||||||||
| ROE | 11.4% | 13.1% | 2.6% | 10.2% | 14.3% | 7.4% | 15.5% | 10.3% | 12.6% | 2.8% | 14.0% |
| ROA | 7.4% | 7.7% | 1.0% | 5.3% | 7.2% | 3.2% | 6.4% | 4.5% | 5.5% | 1.2% | 6.3% |
| Net Profit Margin | 12.2% | 12.8% | 2.1% | 10.6% | 14.3% | 7.3% | 14.1% | 10.0% | 11.7% | 3.1% | 14.3% |
| Debt to Equity | 0.23x | 0.37x | 0.87x | 0.59x | 0.62x | 0.86x | 0.91x | 0.70x | 0.73x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Huahai Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.04%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 205.0%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 546M | 0.36 | 205.0% |
| 2024 | CNY 475M | 0.33 | 42.5% |
| 2023 | CNY 556M | 0.38 | 67.0% |
| 2022 | CNY 147M | 0.10 | 12.6% |
| 2021 | CNY 291M | 0.20 | 59.7% |
| 2020 | CNY 393M | 0.27 | 42.2% |
| 2019 | CNY 209M | 0.14 | 36.7% |
| 2018 | CNY 308M | 0.23 | 286.5% |
| 2017 | CNY 242M | 0.18 | 37.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Jun 8, 2020.
Who owns Zhejiang Huahai Pharmaceutical Co Ltd
- Insiders 42.75%
- Institutions 4.69%
- Public & others 52.56%
- Shares outstanding 1.50B
- Free float 886M
Zhejiang Huahai Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Huahai Pharmaceutical Co Ltd
- Ticker
- 600521.SHG
- ISIN
- CNE000001DL5
- Exchange
- Shanghai Stock Exchange
- Listed since
- Feb 17, 2003
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,797
- Fiscal year end
- December
- Address
- No. 88, Xunda Road, Linhai, China, 317024
- Phone
- 86 576 8501 0288
- Website
- huahaipharm.com
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.
Zhejiang Huahai Pharmaceutical Co Ltd management
10- Mr. Bao Hua ChenGM, President & Director · born 1962
- Ms. Mei ZhangSenior VP & CFO · born 1976
- Mr. Yong Hua ZhuVP, Secretary of the Board & Director · born 1965
- Mr. Sijia GuoExecutive VP & Employee Director · born 1963
- Ms. Yanhua MengVice President · born 1979
- Ms. Lihong LinVice President · born 1973
- Ms. Mi XuVice President · born 1983
- Mr. Qi Mao ChenVice President · born 1958
- Mr. Bo XuVice President · born 1973
- Mr. Dunyuan ChenVice President · born 1967